Clinical Trials Logo
  1. Home
  2. Primary Disease
  3. NCT00552461

Prospective Trial of Rituximab for Primary Pulmonary Alveolar Proteinosis — PAP  

Pulmonary Alveolar Proteinosis Clinical Trial

Official title:
Prospective Open-Label Trial of Rituximab for Primary Pulmonary Alveolar Proteinosis

Clinical Trial Summary

The purpose of this study is to determine whether the use of rituximab is effective in treating pulmonary alveolar proteinosis by leading to an improvement in lung function and disease status.

Clinical Trial Description

The goal of this study is to conduct a prospective, open-label 6-month trial of rituximab in patients who present with symptomatic primary or idiopathic PAP. A total of 10 subjects with primary PAP will be enrolled over 12 months at East Carolina University. Patients over age 18 with a clinical diagnosis of moderate symptomatic idiopathic PAP, established by appropriate clinical history, radiographic and physiologic findings, presence of circulating anti-GM-CSF antibody, and confirmatory findings on bronchoscopy with bronchoalveolar lavage and/or open-lung biopsy will be recruited. Patients with newly diagnosed PAP or established disease may be considered for this study. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00552461
Study type Interventional
Source East Carolina University
Contact
Status Completed
Phase Phase 2
Start date January 2007
Completion date December 2011
View Details
See also
  Status Clinical Trial Phase
Terminated NCT00030056 - GM-CSF in Patients With Pulmonary Alveolar Proteinosis Phase 2
Completed NCT03887169 - Administration of Methionine in Patients With Pulmonary Alveolar Proteinosis by Mutation of the MARS Gene. Phase 1/Phase 2
Completed NCT02468908 - Inhaled Molgramostim (rhGM-CSF) in Healthy Adult Subjects Phase 1
Enrolling by invitation NCT04326036 - Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection Early Phase 1
Completed NCT03007134 - Multicenter International Cross-Sectional Evaluation of Pulmonary Alveolar Proteinosis Trial N/A
Recruiting NCT01983657 - Study of Subcutaneous Injection of Low-dose rhGM-CSF +/- WLL in PAP. Phase 2
Completed NCT04516577 - Updated Severity and Prognosis Score of Pulmonary Alveolar Proteinosis
Recruiting NCT02852928 - European Management Platform for Childhood Interstitial Lung Diseases - chILD-EU Register and Biobank
Completed NCT02081092 - Evaluation and Treatment Planning of Patients With PAP Using Thrive Ultra Short Echo Time MRI and CT
Recruiting NCT03316651 - Sequential Therapy With WLL/Inhaling GM-CSF for Autoimmune Pulmonary Alveolar Proteinosis Phase 2
Enrolling by invitation NCT05300360 - Prevalence of Adenosine Deaminase (ADA) Enzyme Deficiency Disease in Adult Patients With Pulmonary Alveolar Proteinosis
Recruiting NCT02461615 - A National Registry For Pulmonary Alveolar Proteinosis